Tisotumab vedotin extravasation injury in a patient with recurrent cervical cancer

被引：0
|
作者：
Son, Ji [1 ]
Cain, Katherine E. [2 ]
Marten, Claire A. [2 ]
Dwyer, Kaitlin W. [1 ]
Sims, Travis T. [1 ]
Taylor, Jolyn S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Pharm Clin Programs, Houston, TX USA
来源：
GYNECOLOGIC ONCOLOGY REPORTS | 2024年 / 56卷
关键词：
SQUAMOUS-CELL-CARCINOMA; PREVIOUSLY TREATED RECURRENT; PHASE-II; TISSUE FACTOR; PERSISTENT; TRIAL;
D O I：
10.1016/j.gore.2024.101525
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301
    Manso, Luis
    Vergote, Ignace
    Fujiwara, Keiichi
    Angelergues, Antoine
    Zikan, Michal
    Jordan, Scott
    Lee, Jung-Yun
    Barraclough, Lisa
    Maluf, Fernando Cotait
    Lorusso, Domenica
    Yonemori, Kan
    Gennigens, Christine
    Martin, Antonio Gonzalez
    Heitz, Florian
    Westermann, Anneke M.
    Covens, Allan
    Whalley, Elizabeth
    Chen, Yiyi
    Soumaoro, Ibrahima
    Randall, Leslie M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] INNOVATV 301/ENGOT-CX12/GOG-3057: TISOTUMAB VEDOTIN VS INVESTIGATOR'S CHOICE CHEMO IN SECOND- OR THIRD-LINE RECURRENT OR METASTATIC CERVICAL CANCER
    Vergote, I. B.
    Randall, L.
    Kalbacher, E.
    Madsen, K.
    Van Nieuwenhuysen, E.
    Gonzalez-Martin, A.
    Lorusso, D.
    Soumaoro, I.
    Jain, S.
    Slomovitz, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A1 - A1
  • [33] Phase Ib/II trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024).
    Vergote, Ignace
    Concin, Nicole
    Mirza, Mansoor Raza
    Andreassen, Camilla Mondrup
    Lorusso, Domenica
    Gennigens, Christine N.
    Banerjee, Susana N.
    O'Cearbhaill, Roisin Eilish
    Campos, Susana
    Nicacio, Leonardo Viana
    Eaton, Lamar
    O'Malley, David M.
    Soumaoro, Ibrahima
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Tisotumab vedotin versus investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).
    Vergote, Ignace
    Monk, Bradley J.
    Coleman, Robert L.
    Randall, Leslie M.
    Fujiwara, Keiichi
    Marth, Christian
    Woelber, Linn Lena
    Van Nieuwenhuysen, Els
    Cibula, David
    Calvert, Paula
    Boere, Ingrid
    Gonzalez-Martin, Antonio
    Kalbacher, Elsa
    Colombo, Nicoletta
    Lorusso, Domenica
    Banerjee, Susana N.
    Maluf, Fernando C.
    Soumaoro, Ibrahima
    Slomovitz, Brian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Necrotizing Fasciitis of the Cervical Region following Extravasation Injury
    Gundeslioglu, Ayse Ozlem
    Ozen, Emine Cigdem
    CASE REPORTS IN MEDICINE, 2012, 2012
  • [36] The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer
    Texido, Gemma
    Gasparri, Fabio
    Ciavolella, Antonella
    Gianellini, Laura
    Pedersen, Anders E.
    Ocana, Alberto
    Colombo, Riccardo
    Roberti, Domenico
    Mahnke, Lisa
    Perrera, Claudia
    CANCER RESEARCH, 2024, 84 (06)
  • [37] TISOTUMAB VEDOTIN VS INVESTIGATOR'S CHOICE CHEMOTHERAPY IN SECOND- OR THIRD-LINE RECURRENT OR METASTATIC CERVICAL CANCER (INNOVATV 301/ENGOT-CX12/GOG-3057, TRIAL IN PROGRESS)
    Vergote, I.
    Randall, L. M.
    Kalbacher, E.
    Madsen, K.
    Van Nieuwenhuysen, E.
    Gonzalez-Martin, A.
    Cibula, D.
    Monk, B.
    Woelber, L.
    Banerjee, S.
    Westermann, A.
    Colombo, N.
    Lorusso, D.
    Calvert, P.
    Coleman, R. L.
    Marth, C.
    Soumaoro, I.
    Jain, S.
    Slomovitz, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A129 - A130
  • [38] Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
    Coleman, Robert L.
    Lorusso, Domenica
    Gennigens, Christine
    Gonzalez-Martin, Antonio
    Randall, Leslie
    Cibula, David
    Lund, Bente
    Woelber, Linn
    Pignata, Sandro
    Forget, Frederic
    Redondo, Andres
    Vindelov, Signe Diness
    Chen, Menghui
    Harris, Jeffrey R.
    Smith, Margaret
    Nicacio, Leonardo Viana
    Teng, Melinda S. L.
    Laenen, Annouschka
    Rangwala, Reshma
    Manso, Luis
    Mirza, Mansoor
    Monk, Bradley J.
    Vergote, Ignace
    LANCET ONCOLOGY, 2021, 22 (05): : 609 - 619
  • [39] Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma
    Rivasi, Marianna
    Porretta Serapiglia, Carla
    Medici, Gregorio
    Ricchi, Lucia
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024,
  • [40] TRIAL IN PROGRESS OF ENGOT-CX8/GOG-3024/INNOVATV 205: ADDITION OF A NEW COHORT USING FIRST-LINE TISOTUMAB VEDOTIN plus PEMBROLIZUMAB plus CARBOPLATIN ± BEVACIZUMAB IN RECURRENT/METASTATIC CERVICAL CANCER
    Vergote, Ignace
    Mirza, Mansoor
    Sehouli, Jalid
    Lorusso, Domenica
    Kose, Fatih
    Cibula, David
    Westermann, Anneke
    Collins, Dearbhaile
    Banerjee, Susana
    Oaknin, Ana
    Soumaoro, Ibrahima
    Jain, Shweta
    Monk, Bradley
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A225 - A225
12345